TECHBio-Techne
Price
+20%1YEnd-of-day closes, not the intraday tick.
We manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Spatial Biology segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for protein analysis, automated western blot, and multiplexed ELISA workflows.
In the company’s own words · 10-K filed Aug 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Business segments
Q1 2027 · $299.7MThe company’s own SEC segment disclosure.
- United States$152.7M51%
- EMEA, excluding UK$73.9M25%
- China$28.9M9.6%
- APAC, excluding Greater China$22.5M7.5%
- United Kingdom$13.7M4.6%
- Rest of World$8.1M2.7%
Bio-Techne (TECH) reported revenue of $300M in fiscal Q1 2027 (quarter ended Sep 30, 2026), up 4.6% from the same quarter a year earlier. That came with a gross margin of 66% and net income of $28M (9.4% of revenue). For the full year FY2026, revenue was $1.22B (−0.4% year on year) and net income $182M. Its largest region in fiscal Q1 2027 was United States at $153M, 51% of the disclosed total, well ahead of EMEA, excluding UK at 25%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Nov 4, 2026Forward-Looking Statements.Other event · press release
- Sep 23, 2026On September 23, 2026, Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), held a special meeting of shareholders (the “Special Meeting”) to consider and vote on certain proposals related to the Agreement and Plan of Merger, dated as of June 25, 2026 (as it may be amended from time to time in accordance …Shareholder vote results · Form 8-K
- Sep 14, 2026As previously disclosed, on June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Merck KGaA, Darmstadt, Germany”) and EMD Holdings NewCo …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry